Novartis Plans 10% Investment Increase in Saudi

The article focused on Novartis Saudi Arabia's plans to increase its investments in the Kingdom by 10% over the next five years, with an expansion in the local market through increasing the number of locally produced medicines to more than four by 2030, as part of the strategy to localize pharmaceutical industries. The CEO indicated that the company aims to reach 10 million patients in Saudi Arabia by 2030, compared to 5 million currently. Currently, the company has over 140 registered medicines and employs around 200 staff, most of whom are nationals. This aligns with supporting Vision 2030 and the expansion of the healthcare sector in Saudi Arabia.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل